| 3.59 -0.05 (-1.37%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.88 | 1-year : | 5.44 |
| Resists | First : | 4.18 | Second : | 4.66 |
| Pivot price | 3.86  |
|||
| Supports | First : | 3.4 | Second : | 2.82 |
| MAs | MA(5) : | 3.61 |
MA(20) : | 4 |
| MA(100) : | 4.56 |
MA(250) : | 5.22 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 15.7 |
D(3) : | 11.1 |
| RSI | RSI(14): 34.2 |
|||
| 52-week | High : | 8.47 | Low : | 3.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMRX ] has closed above bottom band by 19.3%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.69 - 3.71 | 3.71 - 3.73 |
| Low: | 3.51 - 3.54 | 3.54 - 3.56 |
| Close: | 3.55 - 3.59 | 3.59 - 3.63 |
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Thu, 15 Oct 2026
Immuneering presents lung cancer data as Mizuho keeps Buy for Immuneering stock - ad-hoc-news.de
Sat, 12 Sep 2026
Immuneering's US$36m Market Cap Fall Books Insider Losses - Simply Wall Street
Thu, 10 Sep 2026
84% of evaluable pancreatic cancer patients kept or gained weight after three months - Stock Titan
Thu, 06 Aug 2026
Immuneering Corporation Stock 12‑Month Price Target Cut to $17.57, Implies 300% Upside - TradingView
Wed, 05 Aug 2026
Immuneering Q2 Loss Widens as Cash Runway Extends Into 2029 - Quiver Quantitative
Mon, 27 Jul 2026
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution' - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 13.8 (%) |
| Held by Institutions | 55.4 (%) |
| Shares Short | 15,490 (K) |
| Shares Short P.Month | 14,840 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.95 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -52.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -3.87 |
| PEG Ratio | 0 |
| Price to Book value | 1.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|